NCT07217886View on ClinicalTrials.gov

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

June 5, 2026

Study Completion Date

June 5, 2026

Conditions
Renal Impairment
Interventions
DRUG

S-892216-PO

S-892216-PO tablet will be administered orally.

Trial Locations (4)

32809

Orlando Clicinal Research Center, Orlando

33603

Genesis Clinical Research, Tampa

33705

Global Clinical Professionals (GCP) LLC, St. Petersburg

37920

Alliance for Multispecialty Research (AMR)-Knoxville, Knoxville

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Shionogi

INDUSTRY